Phase I pharmacokinetic study of multicycle high-dose carboplatin followed by peripheral-blood stem-cell infusion in patients with cancer

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
M J JohansenR E Champlin

Abstract

To examine the feasibility of escalating carboplatin area under the concentration-time curve (AUC), using dose predictions based on individual estimates of drug clearance, in a phase I trial of multicycle carboplatin, paclitaxel, and cyclophosphamide chemotherapy with peripheral-blood stem-cell (PBSC) replacement. Forty-four patients (37 breast, seven ovarian) received 165 courses. Initial target carboplatin AUC was 10 mg/ml x min, with interpatient escalation in increments of 25%. Initial carboplatin dose estimates used creatinine clearance (CrCl) to estimate carboplatin clearance. Subsequent clearance and dose estimates were determined using a model incorporating Bayesian estimation and two measured carboplatin plasma ultrafiltrate concentrations. Median clearance was 80.5 mL/min/m2 (range, 41.6 to 131.8). Carboplatin doses up to 2,440 mg/m2 per course were administered without major extramedullary toxicity. Doses varied 2.6-fold at each exposure level. Using the Bayesian model, AUC was predicted with a mean accuracy of 101.2% (83% using CrCl). Ninety-six of 117 courses were within 25% of the target AUC. This model was less biased (0.15 v -2.35 mg/mL x min) and more precise (2.76 v 3.52) in predicting AUC compared with one us...Continue Reading

Citations

Jan 19, 2011·Expert Opinion on Drug Metabolism & Toxicology·Michel Adamina, Markus Joerger
Jun 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A PatnaikM Crump
Nov 25, 2000·Breast Cancer : the Journal of the Japanese Breast Cancer Society·T TajimaM Kubota
Sep 1, 2005·Cancer Chemotherapy and Pharmacology·Jon D HerringtonMark W Riggs
May 10, 2000·Clinical Pharmacokinetics·A RousseauG Lachâtre
Nov 19, 2010·Bioanalysis·Dylan M BachWilliam Clarke
Feb 7, 2003·Fundamental & Clinical Pharmacology·Annick Rousseau, Pierre Marquet
Nov 30, 2007·Journal of Oncology Pharmacy Practice : Official Publication of the International Society of Oncology Pharmacy Practitioners·Lamya Alnaim
Jul 10, 2008·Clinical Pharmacokinetics·Anthe S ZandvlietAlwin D R Huitema
Oct 19, 2000·Anti-cancer Drugs·A D HuitemaJ H Beijnen
May 16, 2012·Therapeutic Drug Monitoring·Mohamed SaleemJennifer H Martin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
R J SchilderR F Ozols
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
R J SchilderR F Ozols
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
G Varuni KondaguntaR J Motzer
© 2021 Meta ULC. All rights reserved